Many drugs for celiac disease are in the pipeline but two are in late-phase clinical trials – Larazotide acetate and latiglutenase. And another that has been getting a lot of buzz lately – AN-PEP or GliadinX.
Refractory celiac disease or RCD is rarely diagnosed. Today’s study demonstrates why RCD is so rare. The study demonstrates that gluten exposure is often the culprit in ongoing celiac disease symptoms.
I often start to write articles and then something else will pop up – a new study or a question from you all. Currently, I have 34 articles that have been started or never finished. Re-reading this one is sort of like re-reading a journal from years ago. It marks a moment in time. Here is a look into what I was thinking on Valentine’s Day this year!
No therapies other than a gluten free diet for life exist for celiac disease. The gluten free diet is insufficient for many to induce complete healing. I’m only talking about healing here. Any exposure to gluten causes damage. A crumb of gluten damages the system as if a celiac sufferer had eaten a piece of bread. The only way to improve our situation is participation in clinical trials!
Over the past 10 years there has been an increase in the number of celiac patients around the world. A few theories regarding the increase in cases are increased awareness, easier screening for celiac, increased hygiene, increased gluten consumption earlier in life, and increased concentration of gluten proteins in wheat. We are going to talk about a recent study evaluating the immunostimulatory parts of wheat.